drugset / Trial / NCT02870634
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
NaSingle-groupOpen-labelTreatment
Summary
Multicenter, open-label , single and multiple dose-escalation and pharmacokinetic study
Timeline
- Start
- 2016-11-16
- Primary completion
- 2019-10-30
- Completion
- 2020-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATSM COPPER (II) | Small molecule | 3 mg | Oral |
| Subject | ATSM COPPER (II) | Small molecule | 6 mg | Oral |
| Subject | ATSM COPPER (II) | Small molecule | 12 mg | Oral |
| Subject | ATSM COPPER (II) | Small molecule | 24 mg | Oral |
| Subject | ATSM COPPER (II) | Small molecule | 48 mg | Oral |